Clinical Trials Browser

Phase 2/3 × INDUSTRY × Laryngeal Neoplasms × Clear all

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04129320 2022-02-08

Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck

Phase 2/3 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Neoplasms

Clinical Trials

HexAgon-HN

Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck